Innovative drugs developed globally are being reported and launched in China for the first time; the Stock Connect Innovative Drug ETF E Fund (159316) has attracted over 2.2 billion in capital in the past three months.

As of 13:07, the Hang Seng Stock Connect Innovative Drug Index (HSSCID) fell by 0.4%. Among the top ten weighted stocks, Innovent Biologics dropped 0.17%, BeiGene dropped 0.55%, CSPC Pharmaceutical Group dropped 0.94%, Akeso dropped 1.31%, China National Pharmaceutical Group dropped 0.78%, Hansoh Pharmaceutical rose 0.19%, Simcere Pharmaceutical dropped 1.1%, Zai Lab dropped 3.25%, and Conroy Biotech-B dropped 0.66%.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) continues to attract capital inflows, with a net capital inflow of 92.2268 million yuan in the previous trading day. As of the previous trading day, the fund had a cumulative net inflow of 229 million yuan over the past week, 181.3 million yuan over the past month, 227.9 million yuan over the past three months, and 702.1 million yuan over the past year.

In terms of news, relevant authorities recently approved the listing of "selective orexin 2 receptor agonists," a new target innovative drug developed and declared simultaneously globally.

Relevant personnel stated that this innovative drug submitted applications for drug marketing registration simultaneously to China, the United States, Japan, and other countries. Our country was the first globally to approve its listing, marking a historic breakthrough in the field of "global new" drug R&D in China, from original target discovery to simultaneous advancement in international multi-center clinical trials, and finally to regulatory approval and listing.

At the same time, the overseas expansion of domestic innovative drugs is accelerating. In the first half of 2026, China's innovative drug industry reached 81 out-licensing collaborations, with a total transaction value of approximately 110 billion US dollars. Chinese companies accounted for 8 out of 10 large-scale global pharmaceutical License Out transactions.

CMB International pointed out that the fundamentals of China's innovative drug industry are strong, and the scale of BD transactions for innovative drugs going global is growing rapidly. The continuous growth in BD transaction volume continuously validates the R&D capabilities of China's innovative drug industry. China's extremely high early-stage R&D efficiency, vast clinical resources, and abundant scientist talent constitute the global competitive advantage of China's innovative drug industry. Driven by strong fundamentals, the valuation repair of the innovative drug sector will continue.

The management fee rate for the Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is 0.15%, the custody fee rate is 0.05%, and the comprehensive fee rate is 0.2%. The lower fee rates can effectively reduce cost expenditures for investors.

The Hang Seng Stock Connect Innovative Drug ETF E Fund (159316) is currently the only ETF product on the market tracking the Hang Seng Innovative Drug Index. It supports T+0 trading, possesses high elasticity and scarcity, and helps investors better seize investment opportunities in Hong Kong stock innovative drugs in this round.